drugset / Trial / NCT01532128

Effect of BIA 9-1067 on Rasagiline Pharmacokinetics

NCT01532128

Phase 1 Completed 24 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the effect of BIA 9-1067 on rasagiline pharmacokinetics in healthy subjects.

Timeline

Start
2009-11
Primary completion
2010-02
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Opicapone Small molecule 50 mg
Subject Rasagiline Small molecule 1 mg

Indications